The stock of Esperion Therapeutics Inc (NASDAQ:ESPR) last traded at $1.73, down -4.95% from the previous session.
ESPR stock price is now -17.00% away from the 50-day moving average and -20.74% away from the 200-day moving average. The market capitalization of the company currently stands at $340.87M.
With the price target of $4, Goldman recently initiated with Neutral rating for Esperion Therapeutics Inc (NASDAQ: ESPR). On December 17, 2024, Cantor Fitzgerald recently initiated its ‘Overweight’ rating on the stock quoting a target price of $8, while ‘BofA Securities’ rates the stock as ‘Underperform’
In other news, Warren Eric, Chief Commercial Officer sold 239 shares of the company’s stock on Feb 19 ’25. The stock was sold for $446 at an average price of $1.87. Upon completion of the transaction, the Chief Commercial Officer now directly owns 159,759 shares in the company, valued at $0.28 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Feb 19 ’25, Chief Financial Officer Halladay Benjamin sold 11 shares of the business’s stock. A total of $20 was realized by selling the stock at an average price of $1.86. This leaves the insider owning 240,671 shares of the company worth $0.42 million. A total of 0.99% of the company’s stock is owned by insiders.
During the past 12 months, Esperion Therapeutics Inc has had a low of $1.58 and a high of $3.94.
The company reported revenue of $51.63 million for the quarter, compared to $33.97 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 52.0 percent.
